Daiichi Sankyo has received conditional approval from Japan’s Ministry of Health, Labour and Welfare for its oncolytic virus Delytact (teserpaturev/G-47delta) to treat malignant glioma.
The approval marks the first-ever oncolytic virus therapy option to patients with glioblastoma and other malignant gliomas that are not controlled with currently available treatments. The therapy is Daiichi Sankyo’s fourth cancer medicine approved in Japan over the past two years.
